

1 **Can ultrasonic biometric indices with optimal cut-offs be a potential screening tool for**
2 **primary angle closure disease? A case-control study**

3 Sheetal Savur^{1,5}, Soujanya Kaup^{1,5} ✉, Anagha Dinesh¹, Siddharudha Shivalli² and Dimple
4 Kondal³.

5
6 ¹ Department of Ophthalmology, Yenepoya Medical College, Yenepoya Deemed to be University,
7 Mangalore, India.

8 ² Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.

9 ³ Public Health Foundation of India, Gurgaon, India.

10 ⁴ Hubert Department of Global Health, Rollins School of Public Health, Emory University,
11 Atlanta, GA, USA.

12 ⁵ These authors contributed equally: Sheetal Savur, Soujanya Kaup. ✉email:

13 drsoujanya@gmail.com

14

15 **Abstract**

16 *Background/ Objectives* : Despite a significant disease burden and potential to cause blindness,
17 primary angle closure disease (PACD) does not have a population-based screening programme.

18 Biometric indices using ultrasound A-scan is a potential tool for glaucoma case-detection.

19 Given that genetic and environmental factors influence these parameters and paucity of data

20 on their discrimination thresholds in Indian populace, we conducted a matched case-control

21 study to determine the biometric indices and their discrimination thresholds associated with

22 PACD.

23 *Methods*: We studied 172 eyes of 86 participants (43 cases;43 controls). We compared the

24 following biometric parameters of cases (PACD, occludable angle $\geq 180^\circ \pm$ raised intraocular

25 pressure) with age and gender matched controls (1:1): Anterior chamber depth (ACD), lens

26 thickness (LT), axial length (AXL), lens position (LP), relative lens position (RLP), lens axial

27 factor (LAF), simple crowding value (Cs), ACD/AXL). We performed conditional logistic

28 regression (to identify factors associated with PACD) and Receiver operating characteristic

29 (ROC) analysis (to determine discrimination thresholds).

30 *Results:* Reduced ACD (Adj OR 0.01; 95% CI: 0.0003-0.15, $p < 0.001$) and increased LT (Adj
31 OR 10.3; 95% CI: 2.42-43.93, $p < 0.001$) were associated with PACD. On ROC analysis, ACD,
32 Cs, and ACD/AXL had optimum sensitivity/specificity at ≤ 3.015 , ≥ 0.056 , and, ≤ 0.1303 ,
33 respectively. ACD (88.4%) and Cs (94.2%) had highest sensitivity and specificity,
34 respectively.

35 *Conclusion:* Ultrasonic biometric parameters differed significantly between PACD and
36 controls. ACD and Cs (at discrimination thresholds of ≤ 3.015 mm and ≥ 0.056 , respectively)
37 using ultrasound A-scan could be a potential tool for PACD case-detection that requires
38 evaluation of its diagnostic yield and cost-effectiveness.

39

40 **Introduction**

41 Glaucoma is the second leading cause of blindness worldwide and an estimated 12 million
42 people are blind due to the disease.(1) Globally, by 2040, the number of people affected by
43 glaucoma is projected to increase to about 112 million, and South Central Asia is projected to
44 record the steepest increase compared to other Asian sub-regions.(2,3) In India, one in every
45 eight persons aged ≥ 40 years has or is at risk of glaucoma.(4) Primary angle closure disease
46 (PACD) is estimated to affect 27.6 million persons in some form or the other.(4) A surge in
47 glaucoma cases is expected in the Indian subcontinent owing to the accelerated growth of
48 population over 40 years of age, overburdening the scarce health resources.(5) Primary angle
49 closure glaucoma (PACG) is more blinding than primary open angle glaucoma, especially in
50 the Indian and Chinese populations.(4) The disease is largely asymptomatic and chronic in
51 India.(6)

52 Blindness from primary angle closure glaucoma can be prevented by established treatments
53 such as laser iridotomy and removal of the crystalline lens.(7,8)

54 Despite the high disease burden and availability of amenable treatment options, glaucoma was
55 not included in the initial five-year priority list of vision 2020 mainly due to a lack of practical
56 and cost-effective population-based strategies, to prevent glaucoma-blindness.(9) Currently it
57 is diagnosed by opportunistic screening.(10) A better understanding of PACD characteristics
58 and its epidemiology, especially in Asia, has offered the potential for screening of risk factors
59 so that timely prophylaxis can be implemented to prevent blindness.(9,11)

60 Although gonioscopy remains the gold standard for diagnosing angle closure, it is subjective
61 and moderately reproducible, thus unsuitable for mass screening.(6,12) Furthermore, routine
62 ophthalmic examination in India, seldom involves gonioscopy, resulting in a low PACD
63 detection rate.(6,10) The flashlight test, a commonly used screening tool in the field, has a low
64 positive predictive value (43.5-45%).(13) Van Herick's test is known to miss a significant
65 number of angle closures and incorrectly identify around 1 in 8 open-angle eyes as closed,
66 even in experienced hands.(14) The newer and expensive non-contact techniques such as the
67 IOL Master, scanning peripheral anterior chamber depth analyzer and anterior segment optical
68 coherence tomography (AS-OCT) have poor to moderate specificity (55.4-84%), and are not
69 suitable for mass screening.(12,15) Over diagnosing PACD (high false positives) will result in
70 excessive referrals and overtreatment of the condition. Ultrasound biomicroscopy permits a
71 detailed evaluation of the angle, but the need for a water bath, supine position, and greater skill
72 of the examiner, makes it an inconvenient screening tool.(16) Evidence suggests that
73 integration of genetic screening is not advantageous in identifying PACD beyond what is
74 achieved with anatomical ocular parameters.(17) Thus, mass screening for PACD remains
75 challenging due to technical difficulties, cost and scalability.

76 In contrast to various screening methods described above, the A-scan ultrasound machine is
77 relatively inexpensive, portable equipment, and an integral part of any cataract treating facility.
78 A technician can be trained with relative ease to obtain accurate scans.(18) Previous studies

79 have explored the association of the following biometric indices with a spectrum of PACD:
80 anterior chamber depth (ACD), axial length (AXL), ACD/AXL, lens thickness (LT), lens axial
81 factor (LAF), relative lens position (RLP) and simple crowding value(Cs).(16,19,20) With an
82 appropriate cut-off point having optimal sensitivity and specificity, these indices can be used
83 as potential surrogates to detect PACD. A few studies have determined these cut-off values
84 among East Asian and Iranian populations. (20–23) Although certain studies from India have
85 assessed few biometric indices, there is a lack of data on optimal cut-offs (discrimination
86 thresholds) to differentiate individuals with and without PACD.(24,25)
87 Given that genetic and environmental factors influence the ocular biometric parameters (26,27)
88 and paucity of data in the Indian populace, we conducted a hospital-based case-control study
89 in a coastal town of South India, with the following objectives

- 90 1. To determine the ultrasonic biometric indices associated with PACD and
- 91 2. To determine the optimal discrimination thresholds of ultrasonic biometric indices to
92 detect PACD.

93 **Methodology**

94 After obtaining approval from Institutional Ethics Committee (Reference number YEC2/258),
95 we conducted this case-control study in the department of ophthalmology of a tertiary care
96 hospital from February to March 2020. The study adhered to the tenets of the Declaration of
97 Helsinki. We obtained written informed consent from the study participants.

98 Inclusion criteria: All consecutive patients ≥ 18 years who consented to take part in the study
99 and who fulfilled the criteria for cases and controls were enrolled.

100 Cases: PACD was defined as those with occludable angle (non-visualisation of posterior
101 trabecular meshwork for $\geq 180^\circ$), on gonioscopy without indentation or manipulation, with or
102 without evidence of raised intraocular pressure (IOP). Undilated fundus examination was

103 performed using indirect ophthalmoscopy with 78D lens wherever possible. Cases who had
104 undergone laser peripheral iridotomy (LPI) were also included as existing evidence suggests
105 that LPI does not affect the biometric variables of the eye including central ACD, LT, AXL.(7)

106 Controls: Subjects who had come for a routine eye examination, correction of refractive errors,
107 lid or ocular surface disorders, or any other issue but with otherwise healthy eyes were
108 considered as controls after matching for age (same calendar year of birth) and gender. One
109 control was selected for each case.

110 Exclusion criteria: All cases of secondary angle closure glaucomas, advanced cataracts (\geq grade
111 III cataracts), previous ocular trauma, intraocular surgeries (other than LPI) or any other
112 condition that prevented gonioscopic examination were excluded.

113 Sample size: Based on reported mean lens thickness in cases (4.52 ± 0.515) and controls
114 (4.235 ± 0.44) (24,28–30), a sample of 43 participants for each group was required, for detecting
115 a true mean difference of 0.285 (i.e. $4.52 - 4.235$) with 80% power and 5% (two sided) level of
116 significance.

117 Data Collection: Demographic data included age and gender. All patients underwent a
118 thorough ophthalmic examination including best corrected visual acuity, slit lamp bio-
119 microscopy, Goldmann applanation tonometry. Wherever possible, we performed an undilated
120 indirect fundus examination using a 78D lens. One of the authors (AD) measured the ultrasonic
121 biometric variables using A-Scan ultrasonography (Echorule Pro, Biomedix Optotechnik &
122 Devices, Bengaluru, India). After anaesthetising the cornea with 0.5% Proparacaine (0.5%
123 Paracaine, Sunways India Pvt Ltd, Ahmedabad, India), A-scan was performed without
124 applying any pressure on the cornea with the subject's gaze fixed on a distant target. We took
125 three successive readings until the standard deviation of AXL and ACD were within 0.3mm

126 and 0.1 mm, respectively. The different ultrasonic biometric variables included LT, ACD, and
127 AXL.

128 We calculated the following composite indices: Lens position (LP)= ACD + 0.5 LT; Relative
129 lens position (RLP) = (LP/AXL); Lens axial factor (LAF) =(LT/AXL)x 10; Simple crowding
130 value (Cs)= (LT -ACD)/AXL.(19,20,31) A senior ophthalmologist (SSav) performed the
131 gonioscopy. We used Goldmann's 3-mirror gonio-lens (Volk optics, Ohio, USA) under
132 standardized conditions namely dim illumination, narrow slit beam with the patient's gaze in
133 primary position.

134 Statistical analysis: We calculated mean value \pm standard deviation for all continuous data. An
135 Independent two-sample t-test was used to compare continuous data between both eyes and
136 also between cases and controls. A p-value <0.05 (two-tailed) was considered statistically
137 significant. Biometric parameters with statistically significant differences between cases and
138 controls were used to build a conditional logistic regression analysis for matched case control
139 study. We plotted receiver operating characteristic (ROC) curves for the independent and
140 composite factors to assess PACD. The area under the ROC curve (AUROC), sensitivity,
141 specificity, and discrimination thresholds were calculated. The most optimal
142 sensitivity/specificity relationship (discrimination thresholds) was determined using Youden's
143 index [(Sensitivity +specificity)-1].(32) We used Stata 15 software (StataCorp. 2017. Stata
144 Statistical Software: Release 15. College Station, TX: StataCorp LLC.) for analysis.

145 **Results:**

146 A total of 62 patients were screened for eligibility and 43 cases (86 eyes) were included (five
147 no consent; ten not eligible and four non-cooperative for Gonioscopy/ A-scan). A total of 51
148 control were approached and 43 (86 eyes) were included (four no consent; four non-
149 cooperative for gonioscopy/ A-scan). The mean age of the participants was 53.47 ± 9.1 years.

150 Most of the participants (72, 83.72%) were females. Observed differences in mean ACD, AXL,
151 and LT among right and left eyes in cases and controls were not statistically significant.
152 On independent sample t-test, the following factors were significantly different among cases
153 and controls: ACD, LT, AXL, LP, RLP, LAF, Cs, ACD/AXL (Table 1). The mean IOP among
154 cases was significantly higher ($20.26\text{mmHg} \pm 5.04$) than controls ($11.95 \text{ mmHg} \pm 1.27$) with
155 $p < 0.001$. Twenty five cases had IOP $> 21\text{mmHg}$ (range: 22 to 32 mmHg).
156 On conditional logistic regression, shorter ACD and increased LT were significantly associated
157 with PACD (Table 2). Every millimetre increase in ACD was associated with 0.01 times lower
158 odds (95% CI: 0.0003-0.15; $p < 0.001$) of PACD. Similarly, every millimetre increase in lens
159 thickness was associated with 10.3 times higher odds of PACD (95% CI: 2.42- 43.93;
160 $p < 0.001$).
161 On ROC curves, ACD, simple crowding value (Cs), and ACD/AXL had optimum sensitivity
162 and specificity with discrimination thresholds of ≤ 3.015 , ≥ 0.056 , and ≤ 0.1303 , respectively
163 (Table 3 and Figure 1).

164 **Discussion:**

165 We found that cases of PACD had significantly shallower anterior chamber and thicker lens
166 (LT) compared to age and gender-matched controls. Eyes with PACD have a
167 disproportionately larger lens compared to their AXL. This is represented by a higher LAF
168 value which was reflected in our study (LAF of cases 1.95, controls 1.7).(19) Eyes with PACD
169 also had more anteriorly situated lenses suggested by the smaller LP and RLP values in the
170 PACD group (LP 4.93 ± 0.41 vs 5.22 ± 0.37 ; RLP 0.218 ± 0.016 vs 0.226 ± 0.016) as compared to
171 the controls. The number of lens fibres in the crystalline lens increases as we age and results in
172 increase in LT. In this study we have tried to negate the effect of age and cataract status on the
173 LT by age-matching and by excluding participants with \geq grade III cataracts. Niu et al described
174 simple crowding value (Cs) as a composite factor of LT, ACD, and AXL associated with angle

175 closure.(20) A larger Cs value indicates a more crowded angle. We found a significantly larger
176 Cs value in the PACD group compared to normal (0.08 ± 0.03 vs 0.03 ± 0.02).

177 On conditional logistic regression, we found that the adjusted odds of PACD were highest for
178 shallower ACD (after adjusting for LT and AXL). ACD is the single most important factor
179 which differentiates PACD from normal eyes.(20) The diagnostic value of ACD for identifying
180 the risk of angle closure has been studied previously.(22,23,33) However, the cut-off values of
181 the ocular biometric parameters differ significantly among different ethnicities as well as
182 different regions. Genetic and environmental factors are known to influence the ocular
183 biometric parameters.(26,27) It is therefore pertinent to determine the region and population-
184 specific optimal discrimination thresholds for the biometric indices.

185 On ROC analysis, ACD had the highest sensitivity (88.4%) at an optimal cut-off value of
186 ≤ 3.015 mm. We considered the distance from the anterior corneal epithelium to the anterior
187 lens surface as the ACD measurement. ACD, therefore, included the central corneal thickness
188 (CCT). The “true” ACD however is the axial distance from the corneal endothelium to the
189 anterior lens surface and does not include CCT (“true” ACD = ACD-CCT).(34) We did not
190 measure the CCT in our study. The average CCT in our population is about 0.536mm.(35)
191 Hence, if we assume a CCT of 0.536mm, the “true” ACD cut-off values would be ≤ 2.479 mm.

192 Many studies do not specify if the ACD was measured from the corneal epithelium or
193 endothelium. The ACD values reported range from 1.53 to 3 mm.(24,25,36) The definition of
194 cases may be variable in different studies (non-visualization of posterior trabecular meshwork
195 ≥ 180 degrees vs 270 degrees), contributing to differences in cut-off values.(22,23) We did not
196 perform indentation Gonioscopy to rule out synechial angle closure nor did we attempt to
197 categorize our cases into Primary angle closure suspect (PACS), Primary angle closure (PAC),
198 and Primary angle closure glaucoma (PACG). It is known that there is a linear trend towards
199 more shallow ACD in cases with PACG vs those with PAC vs PACS.(37) The varying

200 accuracies of different measurement techniques (handheld/immersion ultrasound A-
201 scan/optical pachymeter) could also contribute to ACD variations.(23)

202 We found that simple crowding value (Cs) had the highest specificity (94.2%) at an optimal
203 cut-off of ≥ 0.056 . Nui et al reported the Cs cut-off value as ≥ 0.11 in a study performed using
204 an optical biometer, on Han Chinese patients with acute angle closure glaucoma and not on
205 PACD cases. This could explain the variation in values. ACD/AXL had moderate sensitivity
206 (81.4%) and specificity (86%).

207 Evidence suggests that ocular biometric parameters can be used to predict the risk of
208 PACD.(27) We found ACD and Cs as potential predictors which can be used for mass
209 screening of our population. Currently, in a developing country like India, opportunistic
210 screening when the patient presents to an eye clinic, is the best approach for glaucoma disease
211 detection.(10) The opportunity is however underutilized due to the time-consuming and skilled
212 nature of Gonioscopic examination. Also, the utilisation of gonioscopy as a mass screening
213 tool appears unrealistic to a large extent. These hurdles in PACD screening can be overcome
214 by the utilisation of A-scan.

215 Do we need to screen and treat PACS?

216 Two large clinical trials, the Zhongshan Angle Closure Prevention (ZAP) Trial and the
217 Singapore Asymptomatic Narrow Angles Laser Iridotomy Study have attempted to answer this
218 important question.(38,39) They concluded that although the trials showed that LPI almost
219 halved the risk of progression of PACS (to PAC/PACG/ Acute angle closure), interventions
220 for community-level active case detection of PACS and LPI may not be recommended at a
221 programmatic level in view of lower rates of progression in their trial cohorts. The results of
222 this trial needs to be re-appraised in the Indian context. In the Indian population, PACS has
223 been shown to progress to PAC among 22% cases over a span of five years(40) as compared
224 to 4.05% over six years in the ZAP trial control arm (7.97 per 1000 eye-years) and 9.4% (21.84

225 per 1000 eye-years) in the Singapore study control arms. Also, Indian eyes are more prone to
226 progression to PACG from PAC (28.5% in five years)(41) as compared to Chinese (4.1% in
227 six years)(42). Hence, in view of the rapid progression of the disease in Indian eyes, the cost-
228 effectiveness of PACS screening and LPI need to be re-assessed in the Indian scenario.

229 Also, one in every twelve adults (more than 74 million) in India have diabetes(43) and need
230 repeated dilated fundus examination for diabetic retinopathy screening. Dilatation again can
231 precipitate an attack of angle closure glaucoma in PACS(38). This again illustrates the point
232 that screening for PACS and LPI might still have a role to play in Indian scenario.

233 India has a robust cataract surgical programme.(11) India is one of the well-performing
234 countries with respect to achieving the target cataract surgery rate (CSR) (i.e number of cataract
235 surgeries performed per million population). In the year 2018-19, around 6.6 million cataract
236 surgeries were performed, achieving the target CSR.(44) In 2019-20, 18,306 eye screening
237 camps were conducted across India. (44) In a resource-limited country like India, utilising
238 equipment that is available and widely used for cataract surgery, for screening PACD, would
239 be a good option. There is also evidence suggesting that clear lens extraction is a cost-effective
240 treatment of PAC and PACG.(8) Hence, these subgroups of PACD have emerged as newer
241 indications for cataract surgery. With a common treatment protocol for both the diseases
242 (cataract and PAC/PACG), it is logical to integrate PACD screening using ultrasound A-scan
243 into the existing cataract screening programme.

244

245 **Strengths:** Although biometric parameters have been studied in the context of PACD, there is
246 a dearth of evidence for population-specific optimal discrimination threshold values in our
247 population. This study attempts to fill in this gap in knowledge.

248

249 **Limitations:** Study findings apply to our population or population with similar racial, ethnic
250 and environmental factors. As we did not perform indentation gonioscopy and visual fields, we
251 did not classify PACD as PACS, PAC, and PACG. We did not measure the “true” ACD. The
252 outcome assessor measuring the ultrasonic biometric parameters was not masked to the
253 gonioscopic findings. However, measurement bias was reduced by repeated measurements by
254 a single investigator to obtain values that were within a known acceptable limit of standard
255 deviation. The positive predictive value (the proportion of individuals with a positive result
256 who actually have the disease) is dependent on the prevalence of the condition being tested.
257 Thus, the true utility of this tool in community-level screening needs to be assessed by a large
258 field-based diagnostic accuracy study. Such a study will also be able to address the concerns
259 associated with the sample size and hospital-based nature of this study.

260

261 **Conclusion:**

262 The ultrasonic biometric parameters differed significantly between PACD and normal eyes.
263 ACD and Cs, at discrimination thresholds of ≤ 3.015 mm and ≥ 0.056 , respectively, using
264 hand-held ultrasound A-scan are potential tool for PACD case-detection in our population. The
265 diagnostic yield and cost-effectiveness of incorporating A-scan into ongoing cataract screening
266 programmes need further evaluation.

267

268 **Author Contribution Statement:**

269 SSav: was involved in conceptualising and designing the study, literature search, data
270 collection, performing the tests, manuscript preparation, editing and reviewing. SK was
271 involved in conceptualising and designing the study, literature search, data analysis &
272 interpretation of results, manuscript preparation, editing and reviewing. SK will act as the
273 guarantor of the manuscript. AD was involved in literature search, data acquisition and

274 performing tests, manuscript editing and reviewing. SS and DK: were involved in data analysis,
275 manuscript editing and reviewing.

276 **Conflict of Interest:** The authors declare no competing financial interests.

277 **Funding:** SK is a recipient of the DBT/ Wellcome Trust India Alliance fellowship grant.
278 However, this research received no specific grant from any funding agency in the public,
279 commercial, or not-for-profit sectors

280 **Data availability statement:** The datasets generated during and/or analysed during the current
281 study are available from the corresponding author on reasonable request.

282

283 **Reference:**

- 284 1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al.
285 Global data on visual impairment in the year 2002. Bull World Health Organ.
286 2004;82(11):844–51.
- 287 2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of
288 glaucoma and projections of glaucoma burden through 2040: A systematic review and
289 meta-analysis. Ophthalmology [Internet]. 2014 Nov 1 [cited 2020 Aug
290 4];121(11):2081–90. Available from: <https://pubmed.ncbi.nlm.nih.gov/24974815/>
- 291 3. Chan EWE, Li X, Tham YC, Liao J, Wong TY, Aung T, et al. Glaucoma in Asia:
292 Regional prevalence variations and future projections [Internet]. Vol. 100, British
293 Journal of Ophthalmology. BMJ Publishing Group; 2016 [cited 2020 Aug 20]. p. 78–
294 85. Available from: <http://dx.doi.org/10.1136/bjophthalmol-2014-306102>
- 295 4. George R, Ve RS, Vijaya L. Glaucoma in India: Estimated burden of disease. J
296 Glaucoma [Internet]. 2010 Aug [cited 2020 Aug 12];19(6):391–7. Available from:
297 <https://pubmed.ncbi.nlm.nih.gov/20711029/>
- 298 5. Quigley H, Broman AT. The number of people with glaucoma worldwide in 2010 and

- 299 2020 [Internet]. Vol. 90, British Journal of Ophthalmology. Br J Ophthalmol; 2006
300 [cited 2020 Aug 12]. p. 262–7. Available from:
301 <https://pubmed.ncbi.nlm.nih.gov/16488940/>
- 302 6. Vijaya L, George R, Arvind H, Baskaran M, Ve Ramesh S, Raju P, et al. Prevalence of
303 Primary Angle-Closure Disease in an Urban South Indian Population and Comparison
304 with a Rural Population. The Chennai Glaucoma Study. Ophthalmology [Internet].
305 2008 [cited 2020 Aug 12];115(4):655–61. Available from:
306 <https://pubmed.ncbi.nlm.nih.gov/17869343/>
- 307 7. He M, Friedman DS, Ge J, Huang W, Jin C, Lee PS, et al. Laser Peripheral Iridotomy
308 in Primary Angle-Closure Suspects: Biometric and Gonioscopic Outcomes. The Liwan
309 Eye Study. Ophthalmology [Internet]. 2007 Mar [cited 2020 Aug 12];114(3):494–500.
310 Available from: <https://pubmed.ncbi.nlm.nih.gov/17123610/>
- 311 8. Azuara-Blanco A, Burr J, Ramsay C, Cooper D, Foster PJ, Friedman DS, et al.
312 Effectiveness of early lens extraction for the treatment of primary angle-closure
313 glaucoma (EAGLE): a randomised controlled trial. Lancet [Internet]. 2016 Oct 1 [cited
314 2020 Aug 19];388(10052):1389–97. Available from: www.thelancet.com
- 315 9. Foster PJ, Johnson GJ. Glaucoma in china: How big is the problem? Br J Ophthalmol
316 [Internet]. 2001 [cited 2020 Aug 12];85(11):1277–82. Available from:
317 <https://pubmed.ncbi.nlm.nih.gov/11673287/>
- 318 10. Thomas R. Glaucoma in developing countries. Indian J Ophthalmol. 2012 Sep
319 1;60(5):446–50.
- 320 11. Thomas R, Sekhar GC, Parikh R. Primary angle closure glaucoma: A developing
321 world perspective. Clin Exp Ophthalmol [Internet]. 2007 May [cited 2020 Aug
322 14];35(4):374–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/17539793/>
- 323 12. Lavanya R, Foster PJ, Sakata LM, Friedman DS, Kashiwagi K, Wong TY, et al.

- 324 Screening for Narrow Angles in the Singapore Population : Evaluation of New
325 Noncontact Screening Methods. *Ophthalmology* [Internet]. 2008 [cited 2020 Aug
326 12];115(10). Available from: <https://pubmed.ncbi.nlm.nih.gov/18486215/>
- 327 13. Thomas R, George T, Braganza A, Muliyl J. The flashlight test and van Herick ' s test
328 are poor predictors for occludable angles. *Aust N Z J Ophthalmol* [Internet]. 1996
329 [cited 2020 Aug 12];24(3):251–6. Available from:
330 <https://pubmed.ncbi.nlm.nih.gov/8913128/>
- 331 14. Johnson T V, Ramulu PY, Quigley HA, Singman EL. Low Sensitivity of the Van
332 Herick Method for Detecting Gonioscopic Angle Closure Independent of Observer
333 Expertise. *Am J Ophthalmol* [Internet]. 2018 Nov 1 [cited 2020 Aug 20];195:63–71.
334 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30071210>
- 335 15. Chansangpetch S, Rojanapongpun P, Lin SC. Anterior Segment Imaging for Angle
336 Closure. *Am J Ophthalmol* [Internet]. 2018 Apr 1 [cited 2020 Aug 20];188:xvi–xxix.
337 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29352976>
- 338 16. Dorairaj S, Tsai JC, Grippo TM. Changing Trends of Imaging in Angle Closure
339 Evaluation. *ISRN Ophthalmol* [Internet]. 2012 [cited 2020 Aug 12];2012:1–7.
340 Available from: <https://pubmed.ncbi.nlm.nih.gov/24558589/>
- 341 17. Nongpiur ME, Khor CC, Cheng CY, Husain R, Boey PY, Chew A, et al. Integration of
342 Genetic and Biometric Risk Factors for Detection of Primary Angle Closure
343 Glaucoma. *Am J Ophthalmol*. 2019 Dec 1;208:160–5.
- 344 18. Nolan WP, Baasanhu J, Undraa A, Uranchimeg D, Ganzorig S, Johnson GJ. Screening
345 for primary angle closure in Mongolia: A randomised controlled trial to determine
346 whether screening and prophylactic treatment will reduce the incidence of primary
347 angle closure glaucoma in an east Asian population. *Br J Ophthalmol* [Internet]. 2003
348 Mar 1 [cited 2020 Aug 15];87(3):271–4. Available from:

- 349 <https://pubmed.ncbi.nlm.nih.gov/12598435/>
- 350 19. Markowitz SN, Donald Morin J. The ratio of lens thickness to axial length for
351 biometric standardization in angle-closure glaucoma. *Am J Ophthalmol* [Internet].
352 1985 Apr 15 [cited 2020 Aug 12];99(4):400–2. Available from:
353 <https://pubmed.ncbi.nlm.nih.gov/3885747/>
- 354 20. Niu WR, Dong CQ, Zhang X, Feng YF, Yuan F. Ocular biometric characteristics of
355 Chinese with history of acute angle closure. *J Ophthalmol*. 2018;2018:58357:1–6.
- 356 21. Razeghinejad MR, Banifatemi M. Ocular biometry in angle closure. *J Ophthalmic Vis*
357 *Res* [Internet]. 2013 [cited 2020 Aug 15];8(1):17–24. Available from:
358 <https://pubmed.ncbi.nlm.nih.gov/23825708/>
- 359 22. Congdon NG, Quigley HA, Hung PT, Wang TH, Ho TC. Screening techniques for
360 angle-closure glaucoma in rural Taiwan. *Acta Ophthalmol Scand* [Internet]. 1996
361 [cited 2020 Aug 14];74(2):113–9. Available from:
362 <https://pubmed.ncbi.nlm.nih.gov/8739673/>
- 363 23. Devereux JG, Foster PJ, Baasanhu J, Uranchimeg D, Lee PS, Erdenbeleg T, et al.
364 Anterior chamber depth measurement as a screening tool for primary angle-closure
365 glaucoma in an East Asian population. *Arch Ophthalmol* [Internet]. 2000 [cited 2020
366 Aug 14];118(2):257–63. Available from: <https://pubmed.ncbi.nlm.nih.gov/10676792/>
- 367 24. George R, Paul PG, Baskaran M, Ve Ramesh S, Raju P, Arvind H, et al. Ocular
368 biometry in occludable angles and angle closure glaucoma: A population based survey.
369 In: *British Journal of Ophthalmology* [Internet]. *Br J Ophthalmol*; 2003 [cited 2020
370 Aug 15]. p. 399–402. Available from: <https://pubmed.ncbi.nlm.nih.gov/12642298/>
- 371 25. Sihota R, Lakshmaiah NC, Agarwal HC, Pandey RM, Titiyal JS. Ocular parameters in
372 the subgroups of angle closure glaucoma. *Clin Exp Ophthalmol*. 2000;28(4):253–8.
- 373 26. He M, Wang D, Zheng Y, Zhang J, Yin Q, Huang W, et al. Heritability of Anterior

- 374 Chamber Depth as an Intermediate Phenotype of Angle-Closure in Chinese: The
375 Guangzhou Twin Eye Study. *Invest Ophthalmol Vis Sci* [Internet]. 2008 Jan
376 1;49(1):81–6. Available from: <https://doi.org/10.1167/iovs.07-1052>
- 377 27. Lee RY, Chon BH, Lin S-C, He M, Lin SC. Association of Ocular Conditions With
378 Narrow Angles in Different Ethnicities. *Am J Ophthalmol* [Internet]. 2015 Sep 1 [cited
379 2020 Aug 20];160(3):506-515.e1. Available from:
380 <https://linkinghub.elsevier.com/retrieve/pii/S0002939415003414>
- 381 28. Saxena S, Agrawal PK, Pratap VB, Nath R, Saxena RC. The predictive value of the
382 relative lens position in primary angle-closure glaucoma. *Ann Ophthalmol* [Internet].
383 1993 Dec [cited 2020 Aug 15];25(12):453–6. Available from:
384 <http://www.ncbi.nlm.nih.gov/pubmed/8129328>
- 385 29. Marchini G, Pagliarusco A, Toscano A, Tosi R, Brunelli C, Bonomi L. Ultrasound
386 biomicroscopic and conventional ultrasonographic study of ocular dimensions in
387 primary angle-closure glaucoma. *Ophthalmology* [Internet]. 1998 Nov 1 [cited 2020
388 Aug 15];105(11):2091–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/9818611/>
- 389 30. Nongpiur ME, He M, Amerasinghe N, Friedman DS, Tay WT, Baskaran M, et al. Lens
390 vault, thickness, and position in chinese subjects with angle closure. *Ophthalmology*
391 [Internet]. 2011 Mar [cited 2020 Aug 15];118(3):474–9. Available from:
392 <https://pubmed.ncbi.nlm.nih.gov/21035864/>
- 393 31. Lowe RF. Aetiology of the anatomical basis for primary angle-closure glaucoma.
394 Biometrical comparisons between normal eyes and eyes with primary angle-closure
395 glaucoma. *Br J Ophthalmol* [Internet]. 1970 [cited 2020 Aug 12];54(3):161–9.
396 Available from: <https://pubmed.ncbi.nlm.nih.gov/5428641/>
- 397 32. YODEN WJ. Index for rating diagnostic tests. *Cancer*. 1950 Jan;3(1):32–5.
- 398 33. Nolan WP, See JL, Chew PTKK, Friedman DS, Smith SD, Radhakrishnan S, et al.

- 399 Detection of Primary Angle Closure Using Anterior Segment Optical Coherence
400 Tomography in Asian Eyes. *Ophthalmology* [Internet]. 2007 Jan [cited 2020 Aug
401 12];114(1):33–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17070597>
- 402 34. Aung T, Nolan WP, Machin D, Seah SKL, Baasanhu J, Khaw PT, et al. Anterior
403 chamber depth and the risk of primary angle closure in 2 East Asian populations
404 [Internet]. Vol. 123, *Archives of Ophthalmology*. *Arch Ophthalmol*; 2005 [cited 2020
405 Aug 15]. p. 527–32. Available from: <https://pubmed.ncbi.nlm.nih.gov/15824227/>
- 406 35. Natarajan M, Das K, Jeganathan J. Comparison of central corneal thickness of primary
407 open angle glaucoma patients with normal controls in South India. *Oman J*
408 *Ophthalmol* [Internet]. 2013 [cited 2021 Oct 30];6(1):33. Available from:
409 </pmc/articles/PMC3678195/>
- 410 36. Olurin O. Anterior chamber depths of Nigerians. *Ann Ophthalmol*. 1977
411 Mar;9(3):315–26.
- 412 37. Chen Y-Y, Chen Y-Y, Sheu S-J, Chou P. The biometric study in different stages of
413 primary angle-closure glaucoma. *Eye (Lond)*. 2013 Sep;27(9):1070–6.
- 414 38. He M, Jiang Y, Huang S, Chang DS, Munoz B, Aung T, et al. Laser peripheral
415 iridotomy for the prevention of angle closure: a single-centre, randomised controlled
416 trial. *Lancet (London, England)* [Internet]. 2019 Apr 20 [cited 2022 Jan
417 27];393(10181):1609–18. Available from: <https://pubmed.ncbi.nlm.nih.gov/30878226/>
- 418 39. Baskaran M, Kumar RS, Friedman DS, Lu QS, Wong HT, Chew PTK, et al. The
419 Singapore Asymptomatic Narrow Angles Laser Iridotomy Study: Five-Year Results of
420 a Randomized Controlled Trial. *Ophthalmology* [Internet]. 2022 Feb 1 [cited 2022 Jan
421 28];129(2):147–58. Available from:
422 <http://www.aaojournal.org/article/S0161642021006357/fulltext>
- 423 40. Thomas R, George R, Parikh R, Muliylil J, Jacob A. Five year risk of progression of


- 424 primary angle closure suspects to primary angle closure: a population based study. Br J
425 Ophthalmol [Internet]. 2003 Apr 1 [cited 2022 Jan 27];87(4):450–4. Available from:
426 <https://pubmed.ncbi.nlm.nih.gov/12642309/>
- 427 41. Thomas R, Parikh R, Muliyl J, Kumar RS. Five-year risk of progression of primary
428 angle closure to primary angle closure glaucoma: a population-based study. Acta
429 Ophthalmol Scand [Internet]. 2003 Oct [cited 2022 Jan 27];81(5):480–5. Available
430 from: <https://pubmed.ncbi.nlm.nih.gov/14510795/>
- 431 42. Ye T, Yu Q, Peng S, Wang N, Chen X. [Six year follow-up of suspects of primary
432 angle-closure glaucoma] - PubMed. Zhonghua Yan Ke Za Zhi [Internet]. 1998 [cited
433 2022 Jan 27];34(3):167-9. Available from:
434 <https://pubmed.ncbi.nlm.nih.gov/11877180/>
- 435 43. International Diabetes Federation: India diabetes report 2000 — 2045 [Internet]. 2021
436 [cited 2022 Jan 27]. Available from:
437 <https://www.diabetesatlas.org/data/en/country/93/in.html>
- 438 44. National Programme for Control of Blindness State wise targets & Achievement for
439 various eye diseases during 2018-19 [Internet]. NPCBVI, Government of India -.
440 2018. Available from: <https://npcbvi.gov.in/Home>

441
442
443
444
445
446
447
448

449 **Titles and legends to figures:**

450 **Figure 1:** Fig. 1 Receiver operator characteristic (ROC) curves of the ocular biometric
451 parameters with highest areas under the ROC curve. ROC curve of simple crowding value, Cs
452 solid line with dot), anterior chamber depth, ACD (solid line with square) and ratio of ACD to
453 axial length, ACD/AXL (solid line with triangle) of patients with primary angle closure disease
454 (n = 86) and controls (n = 86) in a coastal town in South India.

455



456

457

458

459

460

461

462 **Table 1: Comparison between different independent ultrasonic parameters and**
 463 **composite indices between cases and controls (n=86 cases; n=86 control)**

Biometric variables	Cases (Mean ± SD)	Controls (Mean ± SD)	Mean difference* (95% Confidence Interval)	p-value
AXL	22.6±0.63	23.1±0.75	-0.48 (-0.69 to -0.27)	<0.001
ACD	2.7±0.34	3.2±0.32	-0.52 (-0.62 to -0.42)	<0.001
LT	4.4±0.49	3.9±0.41	0.47 (0.33 to 0.6)	<0.001
LP	4.9±0.41	5.2±0.37	-0.29 (-0.41 to -0.17)	<0.001
RLP	0.22±0.02	0.23±0.016	-0.008 (-0.013 to -0.003)	0.001
LAF	1.95± 0.21	1.71± 0.17	0.24 (0.182 to 0.3)	<0.001
Cs	0.08± 0.03	0.03± 0.02	0.04 (0.036 to 0.051)	<0.001
ACD/AXL	0.12± 0.01	0.14± 0.01	-0.02 (-0.024 to -0.16)	<0.001

464 AXL= Axial length; ACD= Anterior chamber depth; LT= Lens thickness; LP= Lens position;
 465 RLP= relative lens position; LAF= Lens axial thickness, Cs= Simple crowding value

466
 467 *Difference calculated as Cases minus Control

468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478

479 **Table 2: Conditional logistic regression of independent biometric variables and the**
480 **adjusted odds of primary angle closure disease (n=86 cases; n=86 control)**

481

Biometric variables	Cases	Control	Adjusted Odds ratio (95%CI)	p-value
AXL	22.6±0.63	23.1±0.75	0.60 (0.17, 2.18) *	0.442
ACD	2.7±0.34	3.2±0.32	0.01(0.0003, 0.15) *	0.002
LT	4.4±0.49	3.9±0.41	10.30 (2.42, 43.93) #	0.002

482

483 ACD= Anterior chamber depth; LT= Lens thickness; AXL= Axial length

484 *Adj OR for every millimetre decrease

485 #Adj OR for every millimetre increase

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502 **Table 3: Area under the receiver operating characteristic curve (AUROC), sensitivity,**
 503 **specificity, and discrimination thresholds of biometric variables**

Ultrasonic biometric variables	AUROC (95% CI)	Sensitivity	Specificity	Cut-Off Value (discrimination thresholds)
Anterior chamber depth	0.912 (0.82-0.961)	88.4	88.4	≤ 3.015
Simple crowding value	0.895 (0.843-0.948)	83.7	94.2	≥ 0.056
ACD/AXL ratio	0.879 (0.824-0.933)	81.4	86	≤ 0.130
Lens thickness	0.796 (0.724-0.869)	80.2	82.6	≥ 4.18
Lens position	0.703 (0.625-0.781)	77.9	57	≤ 5.15
Axial length	0.681 (0.601-0.761)	67.4	67.4	≤ 22.85
Lens Axial Factor	0.420 (0.322-0.518)	39.5	86.1	≥ 1.839

504
 505
 506
 507